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Abstract: We evaluated the antidiabetic effects of a mixed vegetable powder-formula I 
(MVP-FI), which is a dry powder mixture of over 65 kinds of vegetables and fruits, using the 
db/db type 2 diabetes mouse model. The db/db mice at 8–10 weeks of age were randomly divided 
into three groups: vehicle treatment, 1.575 g/kg MVP-FI treatment, and 3.15 g/kg MVP-FI 
treatment. During 12 days of treatment, we measured food intake and body weight changes, 
fasting blood glucose levels, and plasma lipid levels. Our results showed that the food intake 
and the body weight of MVP-FI-treated group were decreased gradually. Moreover, the fasting 
blood glucose level of the treated group was signiﬁ  cantly dropped to a normal level comparable 
to that of the lean mice. Furthermore, we also found that the plasma triglyceride level in the 
treated group was dropped, whereas the high-density lipoprotein (HDL) level was increased 
and total cholesterol/HDL-cholesterol ratio was decreased. Taken together, these results suggest 
that the diabetic conditions of the db/db mice have been improved after 12 days treatment with 
MVP-FI. The antihyperglycemic and antiobese activities of the MVP-FI, as demonstrated in 
the present study, may have important clinical implications for improving the management of 
type 2 diabetic patients.
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Introduction
Diabetes, which causes substantial morbidity, mortality, and long-term complications, 
is a predominant public health concern. The disease is characterized by symptomatic 
glucose intolerance as well as alterations in lipid and protein metabolism. It is also an 
important risk factor for cardiovascular disease. With increasing rates of childhood 
and adult obesity, diabetes is likely to become even more prevalent over the coming 
decade (Jia et al 2003; Yeh et al 2003).
Many herbal derivatives or mixtures have been documented in traditional Chinese 
medicine (TCM) as having clinical effectiveness in treating sugar imbalances in dia-
betes (Kimura et al 1999). Some derivatives or mixtures have been found effective 
in treating water retention problems that often accompany diabetes (Jia et al 2003). 
Some Chinese medicines such as Jiang-Tang-Ke-Li and Jin-Qi can reduce the insulin 
resistance and improve the apparent insulin activity (Jia et al 2003; Wang et al 2003). 
To date, hundreds of plants and formulae have been reported that are being used in 
traditional Chinese medicine for the treatment of diabetes (Jia et al 2003).
Mixed vegetable powder-formula I (MVP-FI) contains dry powder of over 65 
kinds of vegetables and fruits including bean sprout, pumpkin, carrot, apple, guava, 
and papaya as reported in a recent study (Wang et al 2007). The antioxidant properties 
of MVP-FI have also been evaluated based on the criteria of oxidative damages to Biologics: Targets & Therapy 2008:2(3) 572
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plasmid DNA, protein oxidation, cell viability, and red blood 
cell deformability. The results indicated that MVP-FI extracts 
provide signiﬁ  cant protections against DNA oxidative dam-
ages and the decreases of the erythrocyte deformability in a 
concentration-dependent manner (Wang et al 2007). The aim 
of our present study was to evaluate the potential antidiabetic 
effects of MVP-FI in the db/db mice, a genetically obese 
diabetic mouse model. Our results clearly demonstrated that 
the diabetic conditions of the db/db mice were signiﬁ  cantly 
improved after 12 days of treatment with MVP-FI.
Materials and methods
Housing and care of animals
Male C57BLKS/J db/db mice were obtained from Jackson 
Laboratory (Bar Harbor, ME, USA). Wild-type C57BL/6J 
mice were purchased from the Laboratory Animal Unit of 
the University of Hong Kong. Mice were housed (3–5 mice 
per cage) in environmentally controlled conditions with a 
12-h light/dark cycle and had free access to standard rodent 
pellet food and water, except when fasted before experiments. 
Adult animals at 8–10 weeks of age were used. All animal 
experiments were approved by the University of Hong Kong 
animal ethics committee on animal research.
Drug preparation and treatment
Mixed vegetable powder-formula I (MVP-FI) was kindly 
provided by Tangeles Biochemical Ltd. Co. (Taiwan, Repub-
lic of China). Before each experiment, MVP-FI was freshly 
dissolved in distilled water (189 g/ml) and used immediately 
to treat the mice. Male C57BLKS/J db/db mice and wild 
type C57BL/6J lean mice were divided randomly and were 
treated orally by gavage with either 3.15 g MVP-FI per kg of 
mouse (High-dose group, n = 4), or 1.575 g MVP-FI per kg 
of mouse (Low-dose group, n = 3), or vehicle only (Control 
group, n = 4), once daily for 12 days. For the treatment 
in C57BL/6J mice, they were gavaged with 3.15 g MVP-FI 
per kg of mouse.
Measurement of food intake and body 
weight changes, fasting blood glucose 
levels, and plasma lipid levels
The food intake and the body weight of each mouse were 
measured every one or two days. Fasting blood glucose lev-
els were measured in tail blood samples of the mice fasted 
for 4 h on day 6 (during treatment) and day 12 (last day of 
treatment). Blood glucose levels were determined using 
the ONETOUCH Ultra Blood Glucose Monitoring System 
(LifeScan Inc., Milpitas, CA, USA). For the measurement 
of plasma lipid levels on day 0 (before treatment) and day 
12 (last day of treatment), blood samples were collected 
from the retro-orbital sinus of the mice. Isoﬂ  urane was used 
to anesthetize animals prior to blood collection. Plasma was 
separated by centrifugation. Total cholesterol (TC), triglyc-
eride, high-density lipoprotein-cholesterol (HDL-C), and 
low-density lipoprotein-cholesterol (LDL-C) levels were 
measured using standard assays.
Intraperitoneal glucose tolerance test
Intraperitoneal glucose tolerance test (IPGTT) was performed 
on day 12. Animals were fasted overnight and then received 
intraperitoneal administration of glucose (2 g/kg). Blood glu-
cose levels were determined using the ONETOUCH Ultra 
Blood Glucose Monitoring System (LifeScan Inc.) from the 
tail blood samples at 0 (before glucose administration), 30, 
60, 90, and 120 min after the glucose administration.
Statistical analysis
Data are expressed as mean ± standard error and analyzed 
by Student’s t test and ANOVA, with P < 0.05 considered 
statistically signiﬁ  cant.
Results
Effect of MVP-FI on food intake 
and body weight
After MVP-FI treatment, the food intake of the mice was 
decreased signiﬁ  cantly (Figure 1). The average body weight 
of adult db/db mice is almost twice of that of the wild-type 
C57BL/6J lean mice. The effects of MVP-FI on body 
weight changes in the db/db mice were shown in Figure 2. 
On day 0, there was no signiﬁ  cant difference among all 
Figure 1 Effect of MVP-FI on the food intake of db/db mice and wild-type C57 lean 
mice. The food intake of the vehicle-treated group and lean group showed a slight 
tendency to decrease from day 0 to day 12. But the food intake of both 1.575 g/kg 
and 3.15 g/kg MVP-FI-treated groups decreased obviously. (Vehicle: n = 4, MVP-FI 
1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4, C57BL/6J lean mice: n = 5).
Abbreviation: MVP-FI, mixed vegetable powder-formula I.
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the treatment groups. The body weights of animals in both 
the vehicle-treated control group and the lean mice group 
showed a slight tendency to increase from day 0 to day 12. 
Contrastingly, the body weights in both the high-dose and 
low-dose MVP-FI treatment groups were gradually reduced. 
From day 6, the body weights of 3.15 g/kg MVP-FI-treated 
db/db mice decreased signiﬁ  cantly. On day 10 and day 
11, the body weights of both treatment groups decreased 
signiﬁ  cantly.
Effect of MVP-FI on fasting blood 
glucose level
Fasting blood glucose levels in the db/db mice and wild-
type C57BL/6J lean mice were measured on day 6 and 
day 12 after the daily treatment with MVP-FI or vehicle. 
As shown in Figure 3, db/db mice treated with vehicle 
had signiﬁ  cantly higher fasting blood glucose levels than 
that of the lean mice. On both day 6 and day 12, blood 
glucose concentrations decreased signiﬁ  cantly in db/db 
mice treated with 3.15 g/kg or 1.575 g/kg MVP-FI when 
comparing with the vehicle treatment group. The db/db 
mice, treated with either 3.15 g/kg or 1.575 g/kg MVP-
FI, were normoglycemic. There was also no signiﬁ  cant 
difference in the fasting blood glucose levels between the 
MVP-FI-treated db/db mice and the wild-type C57BL/6J 
lean mice. Furthermore, the blood glucose concentrations 
of the wild-type C57BL/6J lean mice were not affected in 
response to the treatment with MVP-FI.
Effect of MVP-FI on plasma HDL-C, 
triglyceride levels, and TC/HDL-C ratio
After 12-day treatment, the plasma HDL-C concentrations 
in 3.15 g/kg MVP-FI-treated db/db mice were increased 
(Figure 4). Moreover, the HDL-C levels were signiﬁ  cantly 
higher than those in the vehicle-treated animals. MVP-FI 
also signiﬁ  cantly reduced the plasma triglyceride levels 
in the db/db mice (Figure 5). There were no signiﬁ  cant 
changes in the plasma TC level after treatment with either 
1.575 g/kg or 3.15 g/kg MVP-FI (data not shown). But after 
12 days of treatment, TC/HDL-C ratios of vehicle-treated 
group increased signiﬁ  cantly, and TC/HDL-C ratios of 
3.15 g/kg MVP-FI-treated group decreased signiﬁ  cantly. 
There were no signiﬁ  cant changes in 1.575 g/kg MVP-
FI-treated group (Figure 6). On day 12, TC/HDL-C ratios 
of both 1.575 g/kg and 3.15 g/kg MVP-FI-treated groups 
also decreased signiﬁ  cantly when comparing with that of 
vehicle-treated group.
Effect of 12-day treatment of MVP-FI 
on the glucose tolerance test
Glucose tolerance was evaluated by IPGTT after the 12-day 
treatment in the db/db mice. There was no improvement 
observed in the mice treated with either low or 3.15 g/kg 
MVP-FI (Figure 7).
Discussion
The present study was undertaken to investigate the anti-
diabetic effects of the TCM formula, MVP-FI, using the 
type 2 diabetic db/db mouse model. Our present data clearly 
demonstrate that MVP-FI signiﬁ  cantly improves glucose 
Figure 2 Effect of MVP-FI on the body weight of db/db mice and wild-type C57BL/6J 
lean mice. The body weights of the vehicle-treated group and lean group showed a slight 
tendency to increase from day 0 to day 12. However, the body weights of the MVP-FI-
treated groups were decreased gradually during the treatment period. Before treatment, 
there was no signiﬁ  cant difference in body weights between MVP-FI treatment groups 
and vehicle-treated group (MVP-FI 1.575 g/kg: 34.8 ± 1.24 g, vehicle: 36.2 ± 1.9 g, P  0.05; 
MVP-FI 3.15 g/kg: 35.8 ± 1.89 g, vehicle: 36.2 ± 1.9 g, P  0.05). From day 6, the body 
weights of 3.15 g/kg MVP-FI-treated db/db mice decreased signiﬁ  cantly (Day 6, MVP-FI 
3.15 g/kg: 31.46 ± 1.79 g, vehicle: 36.68 ± 2.54 g, P  0.05; Day 8, MVP-FI 3.15 g/kg: 
30.91 ± 2.1 g, vehicle: 36.61 ± 2.55 g, P  0.05). From day 10, the body weights of both 
MVP-FI treatment groups decreased signiﬁ  cantly (Day 10, MVP-FI 1.575 g/kg: 31.46 ± 
0.35 g, vehicle: 36.64 ± 2.25 g, P  0.01; MVP-FI 3.15 g/kg: 30.4 ± 0.2 g, vehicle: 36.64 ± 
2.25 g, P  0.01. Day 11, MVP-FI 1.575 g/kg: 31.76 ± 0.46 g, vehicle: 37.44 ± 2.55 g, 
P  0.01; MVP-FI 3.15 g/kg: 30.55 ± 0.02 g, vehicle: 37.44 ± 2.55 g, P  0.01). (Vehicle: 
n = 4, MVP-FI 1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4, C57 lean mice: n = 5).
Abbreviation: MVP-FI, mixed vegetable powder-formula I.
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Figure 3 Effect of MVP-FI on the fasting blood glucose concentrations in adult db/db 
mice and wild-type C57BL/6J lean mice. On day 6, glucose levels decreased signiﬁ  cantly 
both in 3.15 g/kg (n = 4, 8.7 ± 1.7 mmol/L) and 1.575 g/kg (n = 3, 8.05 ± 0.65 mmol/L) 
MVP-FI-treated db/db mice (P  0.05 vs. vehicle-treated mice, n = 4, 21 ± 3.48 mmol/L), 
and there was no signiﬁ  cant difference in the levels between MVP-FI-treated db/db 
mice and wild-type C57BL/6J lean mice (n = 5, 6.97 ± 0.2 mmol/L, P > 0.05). On day 
12, fasting blood glucose levels of 3.15 g/kg MVP-FI-treated db/db mice (5.8 ± 1.7 
mmol/L) and 1.575 g/kg MVP-FI-treated db/db mice (9.45 ± 1.5 mmol/L) also had 
signiﬁ  cant decreases when comparing with those of the control db/db mice (treated 
with vehicle, 18 ± 4.7 mmol/L, P  0.05) and had no signiﬁ  cant difference comparing 
with lean mice (8.87 ± 1.1 mmol/L, P  0.05).
Abbreviation: MVP-FI, mixed vegetable powder-formula I.
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homeostasis in the db/db mice. The fasting blood glucose lev-
els went back to normal after 12 days of treatment (Figure 1). 
The results also showed that lean littermate control mice 
were not sensitive to the glucose-lowering effects caused by 
MVP-FI. Furthermore, MVP-FI has noticeably good effects 
on the plasma HDL-C levels and the triglyceride levels. After 
the treatment period, the plasma HDL-C concentrations were 
increased (Figure 3), whereas the plasma triglyceride levels 
were decreased (Figure 4).
It is estimated that more than 200 species of plants exhibit 
hypoglycemic properties, including many common plants, 
such as pumpkin, wheat, celery, wax guard, lotus root, bitter 
melon, ginseng, and papaya (Savickiene et al 2002; Jia et al 
2003). MVP-FI is a traditional Chinese medicine formula 
that contains a mixture of over 65 kinds of vegetables and 
fruits including pumpkin, carrot, apple, guava, and papaya, 
which has been suggested as a drug with nourishing effects, 
especially on the growth and development of the body. It has 
also been found that high ﬁ  bre fruit guava has hypoglycemic 
effect in both mice and human subjects (Cheng and Yang 
1983; Yusof and Said 2004). In general, traditional Chinese 
medicines are complex mixtures of different compounds that 
often act in a synergistic fashion (Tsuneki et al 2004).
In our present study, we found that the body weights 
of MVP-FI-treated groups were decreased (Figure 2). 
Figure 7 Effect of 12-day treatment of MVP-FI on the glucose tolerance test in the 
db/db mice. The results indicated that C57BL/6J lean mice responded normally, with 
the blood glucose level dropped very signiﬁ  cantly at 90 min. However, the glucose 
levels remained high even at 120 min in MVP-FI-treated mice as well as in the vehicle-
treated control db/db mice. (Vehicle: n = 4, MVP-FI 1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: 
n = 4, C57 lean mice: n = 5).
Figure 4 Effect of MVP-FI on the plasma HDL levels in the db/db mice. In the mice 
treated with 3.15 g/kg MVP-FI, the plasma HDL-C levels (0.87 ± 0.045 mmol/L) were 
signiﬁ  cantly higher than those in the vehicle-treated animals (0.4 ± 0.08 mmol/L; a, 
P  0.01) and those at day 0 (0.59 ± 0.06 mmol/L; b, P  0.05). (Vehicle: n = 4, MVP-FI 
1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4).
Abbreviations: HDL-C, high-density lipoprotein-cholesterol; MVP-FI, mixed 
vegetable powder-formula I.
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Figure 5 Effect of MVP-FI on the plasma triglyceride (TG) levels in the db/db mice. After 
12-day treatment, the TG levels decreased signiﬁ  cantly both in 1.575 g/kg (1.3 ± 0.075 
mmol/L vs. day 0 1.83 ± 0.14 mmol/L, P  0.05) and 3.15 g/kg (1.26 ± 0.1 mmol/L vs. 
day 0 1.77 ± 0.11 mmol/L, P  0.05) MVP-FI-treated db/db mice. There is no signiﬁ  cant 
difference in vehicle-treated db/db mice (1.94 ± 0.19 mmol/L vs. day 0 1.83 ± 0.2 mmol/L, 
P > 0.05). (Vehicle: n = 4, MVP-FI 1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4).
Abbreviation: MVP-FI, mixed vegetable powder-formula I.
0
0.5
1
1.5
2
2.5
db vehicle db MVP-F1
(1.575 g/kg)
db MVP-F1
(3.150 g/kg)
T
G
 
(
m
m
o
l
/
L
)
Day 0
Day 12
* *
Figure 6 Effect of MVP-FI on the TC/HDL-C ratios in the db/db mice. Before treatment, 
there was no signiﬁ  cant difference in the TC/HDL-C ratios between MVP-FI treatment 
groups and vehicle-treated group (MVP-FI 1.575 g/kg: 7.2 ± 0.8, vehicle: 6.9 ± 1.0, 
P  0.05; MVP-FI 3.15 g/kg: 6.8 ± 0.8, vehicle: 6.9 ± 1.0 g, P  0.05). After 12 days of 
treatment, TC/HDL-C ratios of vehicle-treated group increased signiﬁ  cantly (Day 12: 
9.32 ± 1.0, Day 0: 6.9 ± 1.0 g, a, P  0.05), and TC/HDL-C ratios of 3.15 g/kg MVP-FI-
treated group decreased signiﬁ  cantly (Day 12: 4.6 ± 0.08, Day 0: 6.8 ±0.8, b, P  0.05). 
There were no signiﬁ  cant changes in 1.575 g/kg MVP-FI-treated group (Day 12: 6.1 ± 
0.5, Day 0: 7.2 ± 0.8, P  0.05). On day 12, TC/HDL-C ratios of both 1.575 g/kg (6.1 ± 
0.5 vs. vehicle-treated group 9.32 ± 1.0, c, P  0.01) and 3.15 g/kg (4.6 ± 0.08 vs. 
vehicle-treated group 9.32 ± 1.0, d, P  0.01) MVP-FI-treated groups also decreased 
signiﬁ  cantly when comparing with that of vehicle-treated group. (Vehicle: n = 4, MVP-FI 
1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4).
Abbreviations: HDL-C, high-density lipoprotein-cholesterol; MVP-FI, mixed 
vegetable powder-formula I; TC, total cholesterol.
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This could be partially related with the decrease in the food 
intake (Figure 1). MVP-FI may affect the appetite and has 
a dual activity of decreasing food intake and increasing 
metabolic rate. On the other hand, in this obese insulin-
resistant db/db mouse model, insulin resistance is often 
accompanied by obesity. Obesity is not only a factor that can 
increase the chance of developing type 2 diabetes, it is also 
independently associated with insulin resistance and other 
morbidity (Kruszynska and Olefsky 1996). Thus, insulin 
resistance in obese type 2 diabetic patients is signiﬁ  cantly 
worse than that in nonobese diabetic individuals. Therapeutic 
agents with both antidiabetic and antiobese effects are 
therefore particularly beneficial. Our results show that 
db/db mice treated with MVP-FI underwent a time-dependent 
reduction in the body weight. Past studies have shown that 
insulin sensitivity in type 2 diabetic patients improves with 
weight loss, possibly because of an improvement in insulin-
stimulated glucose transport into muscle (DeFronzo and 
Ferrannini 1991; Friedman et al 1992; Attele et al 2002). 
A similar mechanism may operate in the MVP-FI-treated 
db/db mice to improve insulin resistance. MVP-FI may 
exert its antidiabetic effects through actions that improve 
insulin sensitivity and the balance between food intake 
and energy expenditure. Future studies will be required to 
identify compounds in the MVP-FI that are responsible for 
its antidiabetic actions.
MVP-FI has strong antidiabetic and lipid-lowering 
properties. Administration with MVP-FI orally to db/db 
mice reduced fasting blood glucose levels (Figure 1). It 
has been found that glucose homeostasis is controlled by 
two kinds of hormones including insulin and anti-insulin 
or counter-regulatory hormones in the gluconeogenesis and 
glycolysis of glucose metabolism and also by the interaction 
between these two kinds of hormones (Pilkis and El-
Maghrabi 1988; Zhang et al 2003). It is well known that the 
changes in the secretion of these hormones bring about the 
changes of the key enzyme activities in glucose metabolism, 
and then affect the production and utilization of glucose in 
the body. The lower fasting blood glucose level observed 
in the treated group suggests a better glycemic control 
in the db/db mice. However, there was no improvement 
observed from the glucose tolerance test (Figure 7). Since 
the mice had been treated for only 12 days in the present 
study, a longer treatment period might be required for 
improving the glucose tolerance in the mice. Furthermore, 
we observed that MVP-FI signiﬁ  cantly reduced the plasma 
triglyceride levels (Figure 5) and increased the plasma 
HDL-C levels (Figure 4) in the db/db mice. A reduction 
of the triglyceride levels and an increase of the HDL-C 
levels caused by MVP-FI may have an important clinical 
signiﬁ  cance, since hyperlipidemia and dyslipidemia are 
often associated with type 2 diabetic patients. TC/HDL-C 
ratio is another established parameter for cardiovascular 
risk factor in humans. Decrease of TC/HDL-C ratio is 
suggested to lower the risk of cardiovascular problems. 
Thus the changes in the lipid proﬁ  le in the MVP-FI-treated 
group are beneﬁ  cial in term of cardiovascular risk. The 
lowering of TC/HDL-C, triglycerides, and fasting blood 
glucose in the MVP-FI-treated group may well be accounted 
for, at least in part, by the reduction in body weight which 
will in turn enhance insulin sensitivity. The fact that there 
was a lowering of fasting blood glucose (largely governed 
by insulin sensitivity) but no difference amongst the 4 
groups in the peak glucose levels in IPGTT would suggest 
improvement in insulin sensitivity rather than glucose-
stimulated insulin secretion by the pancreatic islet cell.
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